TNFRSF1B and acute myeloid leukemia: In a clinical trial of patients with AML, patients received the demethylating agent, azacitidine, and the histone deacetylase inhibitor, panobinostat, which effectively eliminated TNFRSF1B+ Treg cells in peripheral blood and bone marrow (57).